Status:

RECRUITING

Follow-up Study to Monitor the Efficacy and Safety of the Occlutech® mVSD Cases

Lead Sponsor:

Occlutech International AB

Conditions:

Muscular Ventricular Septal Defect

Eligibility:

All Genders

3-80 years

Brief Summary

The Occlutech® mVSD is indicated for percutaneous, transcatheter muscular ventricular septal defect closure device designed for the occlusion of hemodynamically significant muscular ventricular septal...

Detailed Description

This is a multicenter, International, follow-up registry to monitor the efficacy and safety of the Occlutech® mVSD in patients with muscular ventricular septal defects. * Efficacy and safety of impla...

Eligibility Criteria

Inclusion

  • A patient will be eligible for study participation if he/she meets the indication and area of application as laid down in the IFU. Thus, the Occlutech® mVSD is indicated percutaneous, transcatheter muscular ventricular septal defect closure and who are deemed at high risk for surgical intervention after consultation with surgical physicians or as an alternative to surgery with less operational time and recovery period.

Exclusion

  • The device is contraindicated for patients known to have any of the following:
  • An aortic rim of less than 2 mm
  • Patients weighing less than 5.0 kg
  • Sepsis (local or generalized)
  • Perimembranous VSD or post-MI VSD
  • Recent myocardial infarction or a surgical bypass operation in the last 30 days
  • History of repeated pulmonary infection
  • Any type of serious infection 1 month prior to procedure
  • Malignancy where life expectancy is less than 3 years
  • Demonstrated intracardiac thrombi on echocardiography
  • Allergy to anti-platelet or anticoagulant therapy
  • Allergy to nickel and/or titanium and/or nickel/titanium-based materials
  • Intolerance to contrast agents
  • Active bacterial infection

Key Trial Info

Start Date :

March 3 2022

Trial Type :

OBSERVATIONAL

Allocation :

ESTIMATED

End Date :

October 1 2029

Estimated Enrollment :

100 Patients enrolled

Trial Details

Trial ID

NCT05329350

Start Date

March 3 2022

End Date

October 1 2029

Last Update

February 14 2024

Active Locations (1)

Enter a location and click search to find clinical trials sorted by distance.

Page 1 of 1 (1 locations)

1

Gaziantep Unıversıty Hospital

Gaziantep, Şehitkamil, Turkey (Türkiye), 27310